Immunological changes and prevention of disease progression through elotuzumab therapy in refractory IgG4-related sclerosing mesenteritis

Rheumatology (Oxford). 2022 Nov 2;61(11):e334-e336. doi: 10.1093/rheumatology/keac302.

Authors

Sara Comdühr¹, Alexander Dübbers¹, Lars Tharun², Hanna Graßhoff¹, John Stone³, Silke Pitann¹, Gabriela Riemekasten¹, Peter Lamprecht¹

Affiliations

¹ Department of Rheumatology and Clinical Immunology, University of Lübeck.
² Institute for Pathology, University Medical Center of Schleswig-Holstein-Campus Lübeck, Lübeck, Germany.
³ Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

PMID: 35595249
DOI: 10.1093/rheumatology/keac302

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized
Diagnosis, Differential
Disease Progression
Humans
Immunoglobulin G
Panniculitis, Peritoneal* / diagnosis

Substances

elotuzumab
Immunoglobulin G
Antibodies, Monoclonal, Humanized